Keros Therapeutics, Inc.

Pharmaceutical Preparations

KROS Pharmaceuticals & Biotechnology People in Pharmaceuticals & Biotechnology SEC CIK 0001664710 ↗

Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.

Market capitalisation
$219.69M
19,827,188 shares Covers every share class this company has on file.
Insiders on file
5
people who have filed Form 3, 4 or 5 naming this issuer
Value of insider-held stock
$6.25M
from the holdings reported on Forms 3/4/5; this figure has no separate as-of date on file
Insider-held share of market cap
2.85%
insider-held value divided by market capitalisation

What Keros Therapeutics, Inc. reports

Revenue and net income below are for fiscal period FY2025, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.

Revenue
$243.86M
FY2025 annual revenue, from this company’s own annual XBRL filings to the SEC
Net income
$87.01M
FY2025 profit for the period, from this company’s own annual XBRL filings to the SEC
Employees
92
Yahoo Finance
Where the employee count comes from

Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.

Insiders at Keros Therapeutics, Inc.

Shares is what each person last reported holding here.

Everyone below has filed at least one insider report against this company.

Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.

Rows are grouped by the role each person reports.

The role comes from the relationship boxes a person ticks on their own insider filings — officer, director, ten per cent owner — not from anything we infer. Somebody who is both an officer and a director appears once, in the combined group, so the row count still matches the figure at the top of this page. Where no filing states a role we say so instead of guessing one.

People who file insider reports against Keros Therapeutics, Inc..
Insider Reported role Shares Value Last action
Officers who also sit on the board 1
Jasbir Seehra CEO 385,708 $4.37M M Option exercise or conversion Apr 2, 2026 position reported
Directors 4
Julius Knowles Board Member 108,674 $1.23M S Open-market sale Jun 4, 2026 position reported
Carl L. Gordon Board Member 45,057 $510.0K D Disposition to the issuer Nov 21, 2025 position reported
Jean Jacques Bienaime Board Member 7,450 $84.3K P Open-market purchase Aug 17, 2026 position reported
Alpna Seth Board Member 5,250 $59.4K S Open-market sale Jun 4, 2026 position reported

Events from filings

Detected automatically in the filings linked below. Each headline is built from the numbers in those filings, not written by a model. Newest first; events older than 45 days stay listed and are marked as older.

Carl L. Gordon sold 250,000 Keros Therapeutics, Inc. (KROS) shares for $11,002,500 on Aug 13, 2024

Large trade for this person

Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.

Carl L. Gordon sold 250,000 Keros Therapeutics, Inc. (KROS) shares for $11,002,500 on Aug 13, 2024
Date Insider Transaction Shares Price Value Filing
Aug 13, 2024 Carl L. Gordon S Open-market sale 220,600 held after: 899,212 $44.01 $9,708,606 SEC filing ↗
Aug 13, 2024 Carl L. Gordon S Open-market sale 29,400 held after: 119,522 $44.01 $1,293,894 SEC filing ↗

Total of the rows above: $11,002,500, in the currency the filings report.

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Recent insider transactions

Of the 25 rows we hold, 6 are open-market purchases (P) and 5 open-market sales (S) — the only codes we count as buying or selling.

The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.

A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.

Insider transactions disclosed to the SEC for Keros Therapeutics, Inc., newest first, each with the filing behind it.
Date Insider Transaction Shares Price Value Filing
Aug 17, 2026 Jean Jacques Bienaime P Open-market purchase 1,000 $10.27 $10.3K SEC filing ↗
Jul 15, 2026 Jean Jacques Bienaime P Open-market purchase 1,000 $10.61 $10.6K SEC filing ↗
Jun 15, 2026 Jean Jacques Bienaime P Open-market purchase 1,000 $10.19 $10.2K SEC filing ↗
Jun 4, 2026 Julius Knowles S Open-market sale 2,625 $10.73 $28.2K SEC filing ↗
Jun 4, 2026 Alpna Seth S Open-market sale 2,625 $10.72 $28.1K SEC filing ↗
Jun 3, 2026 Julius Knowles A Grant or award 7,142 $0.00 $0 SEC filing ↗
Jun 3, 2026 Alpna Seth A Grant or award 7,142 $0.00 $0 SEC filing ↗
Jun 3, 2026 Jean Jacques Bienaime A Grant or award 7,142 $0.00 $0 SEC filing ↗
May 15, 2026 Jean Jacques Bienaime P Open-market purchase 1,000 $10.58 $10.6K SEC filing ↗
Apr 15, 2026 Jean Jacques Bienaime P Open-market purchase 1,000 $11.70 $11.7K SEC filing ↗
Apr 2, 2026 Jasbir Seehra M Option exercise or conversion 55,000 $0.30 $16.5K SEC filing ↗
Mar 9, 2026 Jean Jacques Bienaime P Open-market purchase 2,000 $11.21 $22.4K SEC filing ↗
Feb 19, 2026 Jasbir Seehra S Open-market sale 7,015 $16.17 $113.4K SEC filing ↗
Nov 21, 2025 Julius Knowles D Disposition to the issuer 130,494 $17.75 $2.32M SEC filing ↗
Nov 21, 2025 Julius Knowles D Disposition to the issuer 191,527 $17.75 $3.40M SEC filing ↗
Nov 21, 2025 Carl L. Gordon D Disposition to the issuer 140,057 $17.75 $2.49M SEC filing ↗
Nov 21, 2025 Carl L. Gordon D Disposition to the issuer 74,465 $17.75 $1.32M SEC filing ↗
Sep 3, 2025 Jasbir Seehra A Grant or award 90,500 $0.00 $0 SEC filing ↗
Jun 4, 2025 Julius Knowles A Grant or award 5,250 $0.00 $0 SEC filing ↗
Jun 4, 2025 Alpna Seth A Grant or award 5,250 $0.00 $0 SEC filing ↗
Jun 4, 2025 Carl L. Gordon A Grant or award 5,250 $0.00 $0 SEC filing ↗
Jun 4, 2025 Jean Jacques Bienaime A Grant or award 5,250 $0.00 $0 SEC filing ↗
Apr 4, 2025 Jasbir Seehra M Option exercise or conversion 49,367 $0.30 $14.8K SEC filing ↗
Aug 13, 2024 Carl L. Gordon S Open-market sale 29,400 $44.01 $1.29M SEC filing ↗
Aug 13, 2024 Carl L. Gordon S Open-market sale 220,600 $44.01 $9.71M SEC filing ↗

From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.

What a Form 4 is

The report an officer, director or large shareholder must file after trading their own company’s stock.

Corporate ownership links — 12 filers hold a position

Who owns Keros Therapeutics, Inc.

Each row is one filer naming this company.

Funds, trusts and other companies file the same ownership forms that executives do. Everything below is taken from those filings, with the position exactly as the filing states it.

Do not add these figures together. 12 of the positions below were reported on filings shared by several filers at once.

Why the same shares appear twice

On a joint filing every named filer is listed against the whole position, so the same block of stock appears under each name. Those rows are marked joint.

Filers holding a position in Keros Therapeutics, Inc.

Funds, trusts and companies that disclose an ownership position in Keros Therapeutics, Inc..
Owner Reported role Shares Filed
ORBIMED ADVISORS LLC Director,Other,TenPercentOwner 45,057 joint
OrbiMed Capital GP VII LLC Director,TenPercentOwner 45,057 joint
OrbiMed Genesis GP LLC Director,TenPercentOwner 45,057 joint
Pontifax (Cayman) IV L.P. TenPercentOwner 10,500 joint
Pontifax (China) IV L.P. TenPercentOwner 10,500 joint
Pontifax (Israel) IV, L.P. TenPercentOwner 10,500 joint
Pontifax Late Stage Fund L.P. TenPercentOwner 10,500 joint
Pontifax Late Stage GP Ltd. TenPercentOwner 10,500 joint
Pontifax Management 4 G.P. (2015) Ltd. TenPercentOwner 10,500 joint
ADAR1 Capital Management GP, LLC TenPercentOwner 0 joint
ADAR1 Capital Management, LLC TenPercentOwner 0 joint
ADAR1 Partners, LP TenPercentOwner 0 joint

See the full ownership map — every entity that files as an owner of a US public company.

Subsidiaries — 2 legal entities

Subsidiaries of Keros Therapeutics, Inc.

2 legal entities named in the subsidiary exhibit filed with this company’s most recent 10-K. . Filing on SEC.gov.

This is not the full list. SEC rules only require a company to name its significant subsidiaries.

What that leaves out

Smaller entities are left out of the exhibit entirely. A short list here means a short exhibit — it does not mean the company owns nothing else. Nothing on this page is inferred: every name below is copied from the filing.

Subsidiaries Keros Therapeutics, Inc. names in its most recent annual report, with the place each one is organised.
Subsidiary Organised in
Keros Security Corporation Massachusetts
Keros Therapeutics Australia, Pty Ltd Australia
What counts as a subsidiary

A subsidiary is a separate legal entity this company controls; it is not the same thing as a brand, a division or an office. These entities do not file with the SEC in their own right, so there is no separate page to open for them.

Think a number here is wrong? Open the linked filing and compare — how to report it.

Sources and technical notes

Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.

Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from Keros Therapeutics, Inc.’s own filings and multiplied by our closing price. Full method.

What that share count means

the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.

We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from Keros Therapeutics, Inc.’s own SEC filings multiplied by the closing price we hold for the same stock.